Skip to main content

Table 1 Legend: Baseline characteristics for both groups. Group A: Fasting for the first half of cycles of chemotherapy and eating a normocaloric diet for the second half of cycles; Group B: Eating a normocaloric diet for the first half of cycles of chemotherapy and fasting for the second half of cycles

From: The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study

Basic characteristics   Total 34 Group A
18 (52.9%)
Group B
16 (47.1%)
Significance
Age at diagnosis   mean: 51.6
(SD 8.4)
(median:51)
Range: 28–69
mean: 49.8
(SD 9.1)
(median:51)
(Range: 28–63
mean: 53.6
(SD 7.3)
(median: 52)
Range:44–69
0.195
Menopausal status premenopausal 24 13 (72.2) 11 (68.7) 0.824
postmenopausal 10 5 (27.8) 5 (31.3)
Tumor entity primary breast cancer 25 (73.5) 12 (66.7) 13 (81.3) 0.691
advanced breast cancer 5 (14.7) 3 (16.7) 2 (12.5)
ovarian cancer 3 (8.8) 2 (11.1) 1 (6.3)
advanced ovarian cancer 1 (2.9) 1 (5.6) 0 (0.0)
T-categories T0 1 (2.9) 0 (0.0) 1 (6.3) 0.323
T1 14 (41.2) 7 (38.9) 7 (43.8)
T2 13 (38.2) 9 (50.0) 4 (25.0)
T3 6 (17.6) 2 (11.1) 4 (25.0)
Nodal status pNx 1 (2.9) 1 (5.6) 0 (0.0) 0.434
pN0 16 (47.1) 7 (38.9) 9 (56.3)
pN1 17 (50.0) 10 (55.6) 7 (43.8)
Grading G1 1 (2.9) 1 (5.6) 0 (0.0) 0.298
G2 17 (50.0) 7 (38.9) 10 (62.5)
G3 16 (47.1) 10 (55.6) 6 (37.5)
Breast cancer intrinsic subtypes (n = 30) Luminal A 3 (10.0) 3 (20.0) 0 (0.0) 0.098
Luminal B / HER2- 11 (36.7) 4 (26.7) 7 (46.7)
Luminal B / HER2+ 4 (13.3) 2 (13.3) 2 (13.3)
triple negative 9 (30.0) 6 (40.0) 3 (20.0)
HER2 overexpressing 3 (10.0) 0 (0.0) 3 (20.0)
Therapy (breast cancer) CT 25 (83.3) 13 (86.7) 12 (80.0) 0.624
CT + Anti-HER2 5 (16.7) 2 (13.3) 3 (20.0)
Therapy (ovarian cancer) CT 3 (75.0) 3 (100.0) 0 (0.0) 0.046
CT + Anti-HER2 + Anti-VEGF 1 (25.0) 0 (0.0) 1 (100.0)
Body Mass Index normal (BMI ≤25) 19 (55.9) 9 (50.0) 10 (62.5) 0.364
overweight (BMI: 25–30) 13 (38.2) 7 (38.9) 6 (37.5)
obese (BMI > 30) 2 (5.9) 2 (11.1) 0 (0.0)